These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31113837)

  • 1. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.
    Weir SJ; Wood R; Schorno K; Brinker AE; Ramamoorthy P; Heppert K; Rajewski L; Tanol M; Ham T; McKenna MJ; McCulloch W; Dalton M; Reed GA; Jensen RA; Baltezor MJ; Anant S; Taylor JA
    J Pharmacol Exp Ther; 2019 Aug; 370(2):148-159. PubMed ID: 31113837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.
    Weir SJ; Dandawate P; Standing D; Bhattacharyya S; Ramamoorthy P; Rangarajan P; Wood R; Brinker AE; Woolbright BL; Tanol M; Ham T; McCulloch W; Dalton M; Reed GA; Baltezor MJ; Jensen RA; Taylor JA; Anant S
    Cell Death Dis; 2021 May; 12(6):562. PubMed ID: 34059639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reposition of the Fungicide Ciclopirox for Cancer Treatment.
    Huang Z; Huang S
    Recent Pat Anticancer Drug Discov; 2021; 16(2):122-135. PubMed ID: 33573561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
    Minden MD; Hogge DE; Weir SJ; Kasper J; Webster DA; Patton L; Jitkova Y; Hurren R; Gronda M; Goard CA; Rajewski LG; Haslam JL; Heppert KE; Schorno K; Chang H; Brandwein JM; Gupta V; Schuh AC; Trudel S; Yee KW; Reed GA; Schimmer AD
    Am J Hematol; 2014 Apr; 89(4):363-8. PubMed ID: 24273151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
    Naesens L; Balzarini J; Bischofberger N; De Clercq E
    Antimicrob Agents Chemother; 1996 Jan; 40(1):22-8. PubMed ID: 8787873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
    Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC
    Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular-Level Control of Ciclopirox Olamine Release from Poly(ethylene oxide)-Based Mucoadhesive Buccal Films: Exploration of Structure-Property Relationships with Solid-State NMR.
    Urbanova M; Gajdosova M; Steinhart M; Vetchy D; Brus J
    Mol Pharm; 2016 May; 13(5):1551-63. PubMed ID: 27019088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ
    Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.
    Mihailidou C; Papakotoulas P; Papavassiliou AG; Karamouzis MV
    Oncotarget; 2018 Feb; 9(12):10360-10374. PubMed ID: 29535812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
    Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
    Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats.
    Shaw JP; Louie MS; Krishnamurthy VV; Arimilli MN; Jones RJ; Bidgood AM; Lee WA; Cundy KC
    Drug Metab Dispos; 1997 Mar; 25(3):362-6. PubMed ID: 9172955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
    Eberhard Y; McDermott SP; Wang X; Gronda M; Venugopal A; Wood TE; Hurren R; Datti A; Batey RA; Wrana J; Antholine WE; Dick JE; Schimmer AD
    Blood; 2009 Oct; 114(14):3064-73. PubMed ID: 19589922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
    J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits.
    Gajdošová M; Vetchý D; Muselík J; Gajdziok J; Juřica J; Vetchá M; Hauptman K; Jekl V
    Int J Pharm; 2021 Jan; 592():120086. PubMed ID: 33188896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro model of infected stratum corneum for the efficacy evaluation of poloxamer 407-based formulations of ciclopirox olamine against Trichophyton rubrum as well as differential scanning calorimetry and stability studies.
    Täuber A; Müller-Goymann CC
    Int J Pharm; 2015 Oct; 494(1):304-11. PubMed ID: 26276254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.
    Weir SJ; Patton L; Castle K; Rajewski L; Kasper J; Schimmer AD
    J Clin Pharm Ther; 2011 Apr; 36(2):128-34. PubMed ID: 21366640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration].
    Kellner HM; Arnold C; Christ OE; Eckert HG; Herok J; Hornke I; Rupp W
    Arzneimittelforschung; 1981; 31(8A):1337-53. PubMed ID: 7197541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.